EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Timing of Magnesium Sulfate Cessation and Apnea of Prematurity in Late‐Preterm Twin Infants

Satoshi Shinohara, Genki Yasuda, Mayuko Kasai, Nobuyuki Katsumata, Atsushi Nemoto, Atsushi Naito, Rei Sunami

Pediatric Pulmonology · 2026-08 · 61 (8)

DOI: 10.1002/ppul.71755 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective To evaluate the association between the timing of maternal magnesium sulfate (MgSO 4 ) discontinuation before delivery and the risk of apnea of prematurity (AOP) in late‐preterm twin infants. Methods This retrospective cohort study included 161 twin pregnancies (322 infants) delivered between 34 0/7 and 36 6/7 weeks at Yamanashi Prefectural Central Hospital (2017–2025). Infants with major anomalies or intrauterine fetal demise were excluded. The primary exposure was the interval between MgSO 4 cessation and delivery, categorized as: no exposure, < 12, 12–24, and ≥ 24 h. Two multivariable logistic regression models were constructed. Model 1 evaluated the association between any maternal MgSO 4 exposure and AOP. Model 2 further incorporated the timing of MgSO 4 discontinuation as a categorical exposure, adjusting for gestational age, chorionicity, small‐for‐gestational‐age status, sex, and 1‐min Apgar score. Results Among the 322 infants, 112 (34.8%) developed AOP. In Model 1, maternal MgSO 4 exposure itself was not significantly associated with AOP. However, in Model 2, delivery within 12 h after cessation of MgSO 4 was independently associated with AOP (adjusted odds ratio, 7.44; 95% confidence interval, 1.48–37.4), whereas longer discontinuation intervals (12–24 or ≥ 24 h) were not. Conclusions Among late‐preterm twin infants, maternal MgSO 4 exposure itself was not independently associated with AOP; however, delivery soon after MgSO 4 discontinuation was associated with an increased risk of AOP. These findings support consideration of MgSO 4 discontinuation timing in perinatal risk assessment and neonatal respiratory monitoring and may help guide future studies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →